IV ubidecarenone: Ph I/II started

Berg began an open-label, U.S. Phase I/II trial to evaluate IV ubidecarenone given over 72 hours twice weekly in 28-day cycles in about 10 patients with GBM that has recurred on an Avastin bevacizumab...